Urokinase (PLAU) Antibody (N-term)
Purified Rabbit Polyclonal Antibody (Pab)
- 产品详情
- 文献引用 : 3
- 实验流程
- 背景知识
Application ![]()
| WB, IHC-P, FC, E |
---|---|
Primary Accession | P00749 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 48523 Da |
Antigen Region | 60-90 aa |
Gene ID | 5328 |
---|---|
Other Names | Urokinase-type plasminogen activator, U-plasminogen activator, uPA, Urokinase-type plasminogen activator long chain A, Urokinase-type plasminogen activator short chain A, Urokinase-type plasminogen activator chain B, PLAU |
Target/Specificity | This Urokinase (PLAU) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 60-90 amino acids from the N-terminal region of human Urokinase (PLAU). |
Dilution | WB~~1:1000 IHC-P~~1:100~500 FC~~1:10~50 E~~Use at an assay dependent concentration. |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | Urokinase (PLAU) Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | PLAU (HGNC:9052) |
---|---|
Function | Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. |
Cellular Location | Secreted. |
Tissue Location | Expressed in the prostate gland and prostate cancers. |
For Research Use Only. Not For Use In Diagnostic Procedures.

Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
REFERENCES
Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002). Sperl, S., et al., Proc. Natl. Acad. Sci. U.S.A. 97(10):5113-5118 (2000). Turkmen, B., et al., Electrophoresis 18(5):686-689 (1997). Conne, B., et al., Thromb. Haemost. 77(3):434-435 (1997). Yoshimoto, M., et al., Biochim. Biophys. Acta 1293(1):83-89 (1996).

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.